Content
Search
Navigation
Sitemap
About us
View this section
View this section
Who we are
Our model
Our investment process
Our NAV Growth Framework
Our purpose, culture and values
Our history
Our people
View this section
View this section
Board of Directors
Portfolio
View this section
View this section
Portfolio data
Late-stage clinical companies
Overview
Autolus Therapeutics
Beacon Therapeutics
Clinical companies
Overview
iOnctura
Spur Therapeutics
Quell Therapeutics
Anaveon
Pre-clinical companies
Overview
Resolution Therapeutics
Purespring Therapeutics
Forcefield Therapeutics
OMass Therapeutics
Mosaic Therapeutics
Kesmalea Therapeutics
Yellowstone Biosciences
Slingshot Therapeutics
Previous portfolio companies
Overview
Gyroscope Therapeutics
Blue Earth
Nightstar
Neogene Therapeutics
14MG
Azeria Therapeutics
Clade Therapeutics
Sustainability
View this section
View this section
Message from CEO, SIML
Our approach to sustainability reporting
Our social impact
Overview
Our patient impact framework
Responsible investor and partner
Overview
Responsible investment process
A responsible partner
Inspiring and empowering our people
Overview
Syncona Fellowship
Responsible and ethical business
Overview
Environment
Our first net zero target
Syncona’s approach to charity
Overview
The Syncona Foundation
Sustainability policies
News and insights
View this section
View this section
News
Insights & articles
Publications & presentations
Investors
View this section
View this section
KPIs
Results and presentations
RNS and inside information
Share price centre
Governance
Overview
Our Committees
How we communicate with our stakeholders
Regulatory publications
Financial calendar
Events calendar
Analysts and advisers
Shareholder information
Overview
Shareholder documents
FAQs
Contact
Portfolio data
Browse all portfolio data news
Search
Latest portfolio data news
Show news from
all companies
all companies
all Late-stage clinical companies companies
all Clinical companies companies
iOnctura
Spur Therapeutics
Quell Therapeutics
Anaveon
all Pre-clinical companies companies
Clear filters
11.12.24
iOnctura reaches new clinical milestones in uveal melanoma
Clinical companies
iOnctura
31.10.24
Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for SBT101, its Gene Therapy Candidate in Adrenomyeloneuropathy (AMN)
Clinical companies
Spur Therapeutics
23.10.24
Spur Therapeutics Showcases Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Oral Presentation at ESGCT 31st Annual Congress
Clinical companies
Spur Therapeutics
22.10.24
Quell Therapeutics to Present Promising Data from Autologous and Allogenic CAR-Treg Programs at Upcoming International Congresses
Clinical companies
Quell Therapeutics
08.07.24
Spur Therapeutics Completes Enrollment in Phase 1/2 GALILEO-1 Trial of FLT201 in Gaucher Disease and Selects Dose for Planned Phase 3 Trial
Clinical companies
Spur Therapeutics
04.06.24
Quell Therapeutics Advances QEL-001, its Multi-modular Engineered CAR-Treg Cell Therapy, into Efficacy Cohort of LIBERATE Phase 1/2 Trial in Liver Transplant Patients
Clinical companies
Quell Therapeutics
Load more
Close menu
About us
View this section
View this section
Who we are
Our model
Our investment process
Our NAV Growth Framework
Our purpose, culture and values
Our history
Our people
View this section
View this section
Board of Directors
Portfolio
View this section
View this section
Portfolio data
Late-stage clinical companies
Overview
Autolus Therapeutics
Beacon Therapeutics
Clinical companies
Overview
iOnctura
Spur Therapeutics
Quell Therapeutics
Anaveon
Pre-clinical companies
Overview
Resolution Therapeutics
Purespring Therapeutics
Forcefield Therapeutics
OMass Therapeutics
Mosaic Therapeutics
Kesmalea Therapeutics
Yellowstone Biosciences
Slingshot Therapeutics
Previous portfolio companies
Overview
Gyroscope Therapeutics
Blue Earth
Nightstar
Neogene Therapeutics
14MG
Azeria Therapeutics
Clade Therapeutics
Sustainability
View this section
View this section
Message from CEO, SIML
Our approach to sustainability reporting
Our social impact
Overview
Our patient impact framework
Responsible investor and partner
Overview
Responsible investment process
A responsible partner
Inspiring and empowering our people
Overview
Syncona Fellowship
Responsible and ethical business
Overview
Environment
Our first net zero target
Syncona’s approach to charity
Overview
The Syncona Foundation
Sustainability policies
News and insights
View this section
View this section
News
Insights & articles
Publications & presentations
Investors
View this section
View this section
KPIs
Results and presentations
RNS and inside information
Share price centre
Governance
Overview
Our Committees
How we communicate with our stakeholders
Regulatory publications
Financial calendar
Events calendar
Analysts and advisers
Shareholder information
Overview
Shareholder documents
FAQs
Contact
Search
Search